In this report, Datamonitor has estimated that there were a total of 2.3 million cases of Parkinson’s disease in 2011 in the seven major markets, with more than a third of these being in the US. Incidence rates are expected to remain constant, while total prevalence rates will increase as a result of the aging population in the seven major markets.
Features and benefits
- Gain insight into market potential, including a robust 10-year epidemiology forecast of prevalent Parkinson's disease cases.
- Understand the key epidemiologic risk factors associated with Parkinson's disease.
Datamonitor expects an increase in prevalent Parkinson's disease cases through to 2021 in the seven major markets as a result of an aging population.
Parkinson’s disease is a lifelong, incurable, yet non-fatal disease; its disease progression leads to an increasing healthcare burden and lower quality of life.
Age, family history, and environmental exposures are important determining factors in Parkinson's disease (PD) prevalence and, with the exception of Japan, men are at a higher risk of developing PD in each of the seven major markets.
Your key questions answered
- What are the most robust epidemiologic studies for Parkinson's disease prevalence data?
- How will the patient population change through to 2021 in the US, Japan, and the five major EU markets (France, Germany, Italy, Spain, and the UK)?
- How do changes in population structure and risk factors affect the trend in prevalent Parkinson's disease cases?